Mettler-Toledo International, Inc.
MTD Healthcare Diagnostics & Research
Mettler-Toledo International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 3.98% from fiscal 2024.
- Revenue
- +4.48%
- EPS
- +18.3%
- Free cash flow
- +33.0%
- Total debt
- −3.29%
Quarter to June 2026, against a year earlier
Follow MTD
Alert me
Mettler-Toledo International, Inc. (MTD) valuation and DCF model
At $1,756.08 the price implies free cash flow after share-based pay growing 16.4% a year for ten years.
Free cash flow after share-based pay grew 10.8% a year over the last ten years, 4.5% over the last five. The price asks for about twice its ten-year rate. The industry’s median company is priced for 15.8%.
In December 2017 the price assumed 18.1% a year; Mettler-Toledo International, Inc. went on to grow free cash flow after share-based pay 10.0% a year to FY2025.
- The price needs
- 16.4% a year for ten years
- $1,756.08
- today’s price
- Its base case
- 10.8% a year for five years, then 6.5%
- $948.57
- 46.0% below today’s price
Base case on its own ten-year record Mettler-Toledo International, Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$8.67b 10 years of cash to equity+$12.78b terminal value−$2.06b net debt=$19.39b equity value÷20.44m shares=$948.57 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 37.65× | 34.40× | 37.33× | 1% above | 34.52× | 9% above | |
| P/FCF | 39.06× | 35.65× | 38.15× | 2% above | 33.51× | 17% above | |
| P/B | 2,631.36× | 865.83× | 551.06× | 378% above | 3.42× | 76856% above | |
| EV/EBITDA | 27.43× | 25.28× | 26.52× | 3% above | 23.44× | 17% above | |
| EV/Sales | 8.66× | 7.99× | 7.83× | 11% above | 5.18× | 67% above |
MTD trades at 2,631.36× P/B, against a 10-year average of 551.06× (range 24.17×–2,631.36×). That is dearer than 100% of the last 7 year-end readings; re-rating to the average implies $367.76 per share.